Respiratory Infections

The new trial comes at a time when the FDA has provided guidance on navigating immunogenicity trials for vaccines designed against more transmissible SARS-CoV-2 strains.

Supporting EUA data for the one-shot vaccine candidate showed Americans fared best in a 40,000-participant, international trial.

This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.

The government-funded trial will seek to interpret the virus' transmissibility and infection, in order to inform vaccination and treatment strategies.

In this era of increasingly mobile and connected populations, it is possible for an infection to spread around the world in 24 to 48 hours.

Preprint data show a US-based variant has come to represent more than 27% and 11% of all sequenced genomes in Louisiana and New Mexico, respectively, through mid-January.

A new study suggests nursing homes with more people of color are actually at three-fold greater risk of COVID-19 mortality.

The EUA follows the authorization for lone therapy bamlanivimab for adults and children at risk of severe COVID-19.

Implications for antimicrobial use and antimicrobial resistance.

New preliminary phase 3 data show the two-dose vaccine may even hold benefit for single-dose use.

Cohort data shows 87% of infants born to mothers with asymptomatic or symptomatic COVID-19 have developed antibodies at birth.

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

After setbacks to its own vaccine candidate, the major drug developer has agreed to aide in production for Europe-bound doses.

New systematic review data suggest most patients who test positive without symptoms will remain asymptomatic over time.

A France-based assessment of the IL-1 inhibitor was ended early on the recommendation of the safety monitoring board early this year.

Avian flu outbreaks have been detected in countries all over the world, but influenza activity in humans remains uncharacteristically low for this point in the season.

An online survey-based assessment showed older adults and minorities have been more likely to wear masks in public.

The agency set a PDUFA date for July 18 for Merck's V114 vaccine.

Ability for rapid diagnosis to treat and prevent communicable diseases is a public health issue that goes beyond the current pandemic.

The discovery of unique virus traits may explain why some patients have more severe responses to the disease.

The ability to monitor, mitigate, and prevent new variant spread could influence the odds of majority immunity.

More transmissible variants are emerging quickly. An expert explains why it's expected, but concerning.

A discussion around the relatively shocking effect of the virus on infants, and what's needed in long-term assessment of the patient group.

From vaccine studies to reopening institutions, pooled testing may be a hugely beneficial tool.